BioAge.
company in Lamezia Terme, Italy
- Reports this week
- 0
- Active events
- 0
- Connections
- 26
What's happening
Gone quiet
No new reports in 90+ days-
BioAge announced that HitGen is partnering with the company in drug development.Some support3 reports
-
Citigroup boosted its price objective on BioAge, and Needham & Company began coverage of the company.Some support3 reports
-
BioAge's BGE-102 was shown to complement existing therapies, specifically GLP-1 agonists.Well supported3 reports
-
BioAge presented clinical data at the American Diabetes Association scientific sessions in Chicago.Speculative1 report
-
BioAge is analyzing samples from the HUNT Biobank in Norway.Some support1 report
-
Kristen Fortney was appointed as the CEO and co-founder of BioAge.Well supported3 reports
-
BioAge participated in a conference held in Boston on August 21, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around BioAge this week
News at the entities that move BioAge most-
Citigroup TransactionalMizuho Securities lowered its price target on Lam Research stock, while Berenberg Bank set a high target and Citigroup reiterated a buy rating.Moves BioAge
-
Jefferies Financial Group OperationalJefferies Financial Group reiterated a buy rating on shares of Essentra plc, which is headquartered in the United Kingdom.Moves BioAge
-
MarketBeat Mentioned togetherMarketBeat identifies Celsius Network as a stock to watch, noting that the company sells products across multiple continents, including Europe.Moves BioAge
-
Needham & Company Mentioned togetherNeedham & Company issued research reports while Mann was identified as the CTO of Kornit Digital.Moves BioAge
-
company Shared contextCompany Q783794 made an announcement originating from Lafox, Illinois, and is listed on Nasdaq.Moves BioAge
Connections
The 9 strongest of 26, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Kristen Fortney Structural
Kristen Fortney serves as the CEO and co-founder of BioAge.
-
GLP Operational
BioAge's technology (BGE-102) is shown to complement and combine with GLP-1 receptor agonists in preclinical models.
-
Citigroup Transactional
Citigroup initiated a price objective action regarding BioAge.
-
Jefferies Financial Group Operational
Jefferies Financial Group provides financial analysis, including price targets and rating changes, for BioAge.
-
Emeryville Shared context
BioAge operates from a location within the city of Emeryville.
-
MarketBeat Mentioned together
MarketBeat publishes information regarding BioAge's stock performance and average ratings.
-
Needham & Company Mentioned together
Needham & Company initiated financial coverage and analysis of BioAge, including price target adjustments.
-
company Shared context
BioAge is categorized as a company.
Show all 9 connections
-
Jin Li Mentioned together
No evidence found regarding any relationship between BioAge and Jin Li.
History
Events by the month they beganJuly 2026
2 eventsJune 2026
5 events- BioAge's BGE-102 was shown to complement existing therapies, specifically GLP-1 agonists.
- BioAge presented clinical data at the American Diabetes Association scientific sessions in Chicago.
- BioAge is analyzing samples from the HUNT Biobank in Norway.
- Kristen Fortney was appointed as the CEO and co-founder of BioAge.
- BioAge participated in a conference held in Boston on August 21, 2025.